Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All

Desalted DNA Oligonucleotides

November 10, 2011 7:45 am | Product Releases | Comments

Integrated DNA Technologies now offers its customers the ability to order RxnReady oligonucleotides. Users can specify the premixing of 2 – 6 standard desalted DNA oligos, in a single tube, according to the individual specifications provided.

TOPICS:

Real-Time PCR System

November 10, 2011 7:39 am | Product Releases | Comments

Thermo Fisher Scientific Inc. has introduced its PikoReal Real-Time PCR Systems, which complete its molecular biology workflow. Available in 24- and 96-well formats, the PikoReal offers performance in a small bench-top footprint.

TOPICS:

MPI VP Serota Elected ACT President

November 10, 2011 6:58 am | News | Comments

MPI Research has announced that David Serota, PhD, DABT, senior vice president of drug safety development and senior principal study director, will serve as the 2012 American College of Toxicology president.

Advertisement

Merck Launches Birth Control Implant

November 10, 2011 6:54 am | News | Comments

Merck & Co. said it has launched the long-acting birth control implant Nexplanon in the United States. Nexplanon has been approved by the Food and Drug Administration for the prevention of pregnancy in women for up to three years.

TOPICS:

FDA Accepts Vismodegib NDA

November 10, 2011 6:49 am | News | Comments

Genentech announced that the U.S. Food and Drug Administration has accepted and filed the company’s New Drug Application for vismodegib for the treatment of adults with advanced basal cell carcinoma for whom surgery is considered inappropriate.

TOPICS:

Sinovac Reports Phase 2 Trial Results

November 10, 2011 6:19 am | News | Comments

Sinovac Biotech Ltd. announced positive top-line results from its Phase 2 clinical trial for its inactivated vaccine against human enterovirus 71, which causes hand, foot and mouth disease.

TOPICS:

Merck to Seek Approval for 8 New Drugs

November 10, 2011 6:14 am | News | Comments

Merck & Co. plans in the next two years to seek U.S. approval for eight new medicines and has other promising drugs in late-stage testing, including drugs for chronic insomnia, hardening of the arteries, osteoporosis, and reversal of anesthesia.

TOPICS:

Affymax Shrinks Quarterly Loss

November 10, 2011 6:09 am | News | Comments

Biotech drugmaker Affymax Inc. reported a smaller third-quarter loss and said it settled litigation with Johnson & Johnson over its top drug candidate, the anemia treatment peginesatide.

TOPICS:
Advertisement

Medivation Loses $10M in Q3

November 10, 2011 6:07 am | News | Comments

Medivation Inc. reported a bigger third-quarter loss than it did a year earlier as it continued to develop treatments for prostate cancer and Alzheimer's disease.

TOPICS:

Pharmacists File Antitrust Suit Against Pfizer

November 10, 2011 6:02 am | News | Comments

A group of California pharmacies are accusing Pfizer Inc. and a generic drug maker of conspiring to keep the price of cholesterol-fighting Lipitor artificially high.

TOPICS:

Microneedle Patches for Polio Vaccinations Get Funding Boost

November 9, 2011 11:34 am | News | Comments

The Georgia Institute of Technology will receive funding through Grand Challenges Explorations, an initiative created by the Bill and Melinda Gates Foundation that enables researchers to test ideas that address health and development challenges.

Oral Treatment Regimen Achieves 90% Sustained Virologic Response

November 9, 2011 11:31 am | News | Comments

Bristol-Myers Squibb  announced results from a 10- patient sentinel cohort of an ongoing Phase 2 study in which treatment with a dual, all-oral direct-acting antiviral regimen of the investigational NS5A replication complex inhibitor daclatasvir and the investigational NS3 protease inhibitor asunaprevir achieved undetectable viral load.

NY Genome Center, 11 Others Collaborate

November 9, 2011 11:26 am | News | Comments

The New York Genome Center launched a collaborative venture in genomic medicine with eleven private and academic medical centers.

TOPICS:

Corkscrew Mechanism May Provide Cancer Therapy

November 9, 2011 11:19 am | News | Comments

Scientists from the universities of Zurich and Duisburg-Essen discovered a specific function of the protein p97/VCP, demonstrating that the protein repairs DNA breaks like a corkscrew.

How Brain Cells Degrade Protein Aggregates

November 9, 2011 11:15 am | News | Comments

Researchers at the Riken Brain Science Institute have discovered a mechanism responsible for selectively degrading aggregates of ubiquitinated proteins from the cell.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading